RESUMO

BACKGROUND: Diagnosing tuberculosis in children is challenging because specimens are difficult to obtain and contain low tuberculosis concentrations, especially with HIV-coinfection. Few studies included well-controls so test specificities are poorly defined. We studied tuberculosis diagnosis in 525 children with and without HIV-infection. METHODS AND FINDINGS: 'Cases' were children with suspected pulmonary tuberculosis (n = 209 HIV-negative; n = 81 HIV-positive) and asymptomatic 'well-control' children (n = 200 HIV-negative; n = 35 HIV-positive). Specimens (n = 2422) were gastric aspirates, nasopharyngeal aspirates and stools analyzed by a total of 9688 tests. All specimens were tested with an in-house hemi-nested IS6110 PCR that took <24 hours. False-positive PCR in well-controls were more frequent in HIV-infection (P≤0.01): 17% (6/35) HIV-positive well-controls versus 5.5% (11/200) HIV-negative well-controls; caused by 6.7% (7/104) versus 1.8% (11/599) of their specimens, respectively. 6.7% (116/1719) specimens from 25% (72/290) cases were PCR-positive, similar (P>0.2) for HIV-positive versus HIV-negative cases. All specimens were also tested with auramine acid-fast microscopy, microscopic-observation drug-susceptibility (MODS) liquid culture, and Lowenstein-Jensen solid culture that took ≤6 weeks and had 100% specificity (all 2112 tests on 704 specimens from 235 well-controls were negative). Microscopy-positivity was rare (0.21%, 5/2422 specimens) and all microscopy-positive specimens were culture-positive. Culture-positivity was less frequent (P≤0.01) in HIV-infection: 1.2% (1/81) HIV-positive cases versus 11% (22/209) HIV-negative cases; caused by 0.42% (2/481) versus 4.7% (58/1235) of their specimens, respectively. CONCLUSIONS: In HIV-positive children with suspected tuberculosis, diagnostic yield was so low that 1458 microscopy and culture tests were done per case confirmed and even in children with culture-proven tuberculosis most tests and specimens were false-negative; whereas PCR was so prone to false-positives that PCR-positivity was as likely in specimens from well-controls as suspected-tuberculosis cases. This demonstrates the importance of control participants in diagnostic test evaluation and that even extensive laboratory testing only rarely contributed to the care of children with suspected TB. TRIAL REGISTRATION: This study did not meet Peruvian and some other international criteria for a clinical trial but was registered with the ClinicalTrials.gov registry: ClinicalTrials.gov NCT00054769.

Assuntos

RESUMO

BACKGROUND: Campylobacter jejuni and Campylobacter coli are food-borne pathogens of great importance and feature prominently in the etiology of developing world enteritis and travellers' diarrhoea. Increasing antimicrobial resistant Campylobacter prevalence has been described globally, yet data from Peru is limited. Our objective was to describe the prevalence trends of fluoroquinolone and macrolide-resistant C. jejuni and C. coli stool isolates from three regions in Peru over a ten-year period. METHODS: Surveillance for enteric pathogens was conducted in Lima, Iquitos and Cusco between 2001 and 2010. Campylobacter stool isolates were tested for susceptibilities to ciprofloxacin, azithromycin and erythromycin. Susceptibilities were reviewed for 4652 isolates from Lima ( n = 3419), Iquitos ( n = 625) and Cusco ( n = 608). RESULTS: Comparing the study periods of 2001-2005 and 2006-2010, prevalence of ciprofloxacin-resistant C. jejuni isolates rose in the study areas of Lima (73.1% to 89.8%, p < 0.001) and Iquitos (24.1% to 48.9%, p < 0.001). Ciprofloxacin-resistant C. coli rates also increased in Lima (48.1% to 87.4%, p < 0.001) and Cusco (10.0% to 65.9%, p = 0.005). Small but significant increases in azithromycin-resistant and erythromycin-resistant C. jejuni prevalence were noted in Iquitos (2.2% to 14.9%, p < 0.001; 3.2% to 14.9%, p = 0.002), and erythromycin-resistant C. coli rates increased in Lima (0.0% to 5.3%, p = 0.038). The prevalence of C. jejuni isolates resistant to both ciprofloxacin and azithromycin increased in Iquitos (0.3% to 14.9%, p < 0.001) and Lima (0.3% to 1.6%, p = 0.011), and prevalence of C. jejuni isolates resistant to both ciprofloxacin and erythromycin rose in Iquitos (0.0% to 14.9%, p < 0.001). Ciprofloxacin and erythromycin resistant C. coli prevalence increased in Lima (0.0% to 5.3%, p = 0.034). CONCLUSIONS: These results have implications for the empirical management of enterocolitis in Peru. Ongoing surveillance is essential to guide appropriate antimicrobial use in this setting. Local epidemiological studies to explore the relationship between increasing antimicrobial resistance and agricultural or human antibiotic use may be valuable.

Assuntos

RESUMO

BACKGROUND: The diagnosis of pulmonary tuberculosis presents challenges in children because symptoms are non-specific, specimens are difficult to obtain, and cultures and smears of Mycobacterium tuberculosis are often negative. We assessed new diagnostic approaches for tuberculosis in children in a resource-poor country. METHODS: Children with symptoms suggestive of pulmonary tuberculosis (cases) were enrolled from August, 2002, to January, 2007, at two hospitals in Lima, Peru. Age-matched and sex-matched healthy controls were enrolled from a low-income shanty town community in south Lima. Cases were grouped into moderate-risk and high-risk categories by Stegen-Toledo score. Two specimens of each type (gastric-aspirate, nasopharyngeal-aspirate, and stool specimens) taken from each case were examined for M tuberculosis by auramine smear microscopy, broth culture by microscopic-observation drug-susceptibility (MODS) technique, standard culture on Lowenstein-Jensen medium, and heminested IS6110 PCR. Specimens from controls consisted of one nasopharyngeal-aspirate and two stool samples, examined with the same techniques. This study is registered with ClinicalTrials.gov, number NCT00054769. FINDINGS: 218 cases and 238 controls were enrolled. 22 (10%) cases had at least one positive M tuberculosis culture (from gastric aspirate in 22 cases, nasopharyngeal aspirate in 12 cases, and stool in four cases). Laboratory confirmation of tuberculosis was more frequent in cases at high risk for tuberculosis (21 [14.1%] of 149 cases with complete specimen collection were culture positive) than in cases at moderate risk for tuberculosis (one [1.6%] of 61). MODS was more sensitive than Lowenstein-Jensen culture, diagnosing 20 (90.9%) of 22 patients compared with 13 (59.1%) of 22 patients (p=0.015), and M tuberculosis isolation by MODS was faster than by Lowenstein-Jensen culture (mean 10 days, IQR 8-11, vs 25 days, 20-30; p=0.0001). All 22 culture-confirmed cases had at least one culture-positive gastric-aspirate specimen. M tuberculosis was isolated from the first gastric-aspirate specimen obtained in 16 (72.7%) of 22 cases, whereas in six (27.3%), only the second gastric-aspirate specimen was culture positive (37% greater yield by adding a second specimen). In cases at high risk for tuberculosis, positive results from one or both gastric-aspirate PCRs identified a subgroup with a 50% chance of having a positive culture (13 of 26 cases). INTERPRETATION: Collection of duplicate gastric-aspirate specimens from high-risk children for MODS culture was the best available diagnostic test for pulmonary tuberculosis. PCR was insufficiently sensitive or specific for routine diagnostic use, but in high-risk children, duplicate gastric-aspirate PCR provided same-day identification of half of all culture-positive cases.

Assuntos

RESUMO

BACKGROUND & AIMS: Diosmectite is a clay used to treat children with acute watery diarrhea. However, its effects on stool output reduction, the key outcome for pediatric antidiarrheal drugs, have not been shown. METHODS: Two parallel, double-blind studies of diosmectite efficacy on stool reduction were conducted in children 1 to 36 months old in Peru (n = 300) and Malaysia (n = 302). Inclusion criteria included 3 or more watery stools per day for less than 72 hours and weight/height ratios of 0.8 or greater. Exclusion criteria were the need for intravenous rehydration, gross blood in stools, fever higher than 39 degrees C, or current treatment with antidiarrheal or antibiotic medications. Rotavirus status was determined. Diosmectite dosage was 6 g/day (children 1-12 months old) or 12 g/day (children 13-36 months old), given for at least 3 days, followed by half doses until complete recovery. Patients were assigned randomly to groups given diosmectite or placebo, in addition to oral rehydration solution (World Health Organization). RESULTS: Children in each study had comparable average ages and weights. The frequencies of rotavirus infection were 22% in Peru and 12% in Malaysia. Similar amounts of oral rehydration solution were given to children in the diosmectite and placebo groups. Stool output was decreased significantly by diosmectite in both studies, especially among rotavirus-positive children. In pooled data, children had a mean stool output of 94.5 +/- 74.4 g/kg of body weight in the diosmectite group versus 104.1 +/- 94.2 g/kg in the placebo group (P = .002). Diarrhea duration was reduced by diosmectite, which was well tolerated. CONCLUSIONS: These results show that diosmectite significantly decreased stool output in children with acute watery diarrhea, especially those who were rotavirus-positive.

Assuntos

RESUMO

BACKGROUND: Acute diarrhea is an important cause of morbidity and mortality in children. Oral rehydration salts (ORS) have lowered mortality without having an effect on the duration or severity of diarrhea. Some studies have reported that heat-killed Lactobacillus bacteria have a beneficial effect in the treatment of acute diarrhea. In this placebo-controlled study the duration of diarrhea was compared for 2 types of treatment: Lactobacillus LB (Lacteol) in association with oral rehydration and oral rehydration alone. PATIENTS AND METHODS: A total of 80 nondehydrated children between the ages of 3 months and 4 years with acute watery diarrhea were randomly assigned to be treated with Lactobacillus LB or placebo plus ORS. The primary endpoint was the duration of diarrhea; intake of ORS and change in body weight between the time of randomization and the last assessment were also measured. RESULTS: In 71 of the 80 patients, diarrhea was resolved: 36 in the Lactobacillus LB group and 35 in the placebo group. Several clinical characteristics of the 2 treatment groups were comparable at baseline. Median duration of diarrhea was 16.6 hours in the placebo group compared with 10.0 hours in the Lactobacillus LB group (P = 0.275). In the subgroup with a duration of diarrhea of more than 24 hours at inclusion, duration of diarrhea measured from that point was shorter for the Lactobacillus LB group (30.4 h vs 8.2 h; P = 0.044). ORS intake was similar for both groups. Lactobacillus LB was well tolerated, with only one patient experiencing an adverse effect. CONCLUSIONS: Lactobacillus LB is an effective and safe treatment for children with well-established diarrhea (>24 h).

Assuntos

RESUMO

BACKGROUND: Adjuvant therapy to ORT with probiotic bacteria for infants with acute watery diarrhea has been under active investigation. Most studies have been done in the developed world showing benefit only for viral mild gastroenteritis. We evaluated the effect of a milk formula containing one billion (109) cfu/ml of Lactobacillus casei strain GG (LGG) upon duration and severity of diarrhea in infants in an environment with more severe acute diarrhea, where etiologic agents other than rotavirus are involved more frequently, and where mixed infections are more prevalent. METHODS: Male infants aged 3-36 months brought for treatment of acute watery diarrhea of less than 48 hours were eligible. After rehydration was completed with the WHO's oral rehydration solution, patients were randomly assigned to receive a milk formula either containing LGG or not. Stool volume was periodically measured using a devise suited to collect stools separate from urine. Duration of diarrhea was estimated based on stools physical characteristics. RESULTS: Eighty nine patients received the placebo milk formula and ninety received the LGG containing formula. Both groups were comparable in their baseline characteristics. Total stool output was significantly larger (p = 0.047) in the LGG group (247.8 ml/kg) than in the placebo group (195.0 ml/kg). No significant differences were found in duration of diarrhea (58.5 hours with LGG vs. 50.4 hours with placebo), rate of treatment failure (21.1% with LGG vs. 18.0% with placebo), and proportion of patients with unresolved diarrhea after 120 hours (12.2% with LGG vs. 12.5% with placebo). The rate of stools with reducing substances after 24 hours of treatment increased significantly in both groups (from 41.4% to 72.2% with LGG and from 45.9% to 68.0% with placebo). CONCLUSION: This study did not show a positive effect of LGG on the clinical course of acute watery diarrhea. Positive beneficial effects of LGG, as had been reported elsewhere, could have been masked in our study by worsening diarrhea due to transient lactose malabsorption. Further studies with low-lactose or non-lactose conveyors of LGG are desirable.

Assuntos

RESUMO

We report the case of a patient with Hemoglobin S / Thalassemia. It is feasible to recognize this infrequent disease by its clinical presentation and the aid of clinical laboratory. On this patient, the diagnosis was established based on the clinical findings, hematological evaluation (with careful observation of the red cell morphology and reticulocyte count) and electrophoretic analysis of hemoglobin. We discusse the physiopathology, clinical manifestations, treatment and alternative of prevention of this disease.

Assuntos

RESUMO

En el presente estudio se intentó detectar la presencia del gen de toxina en cepas locales de Escherichia Coli serológicamente relacionados a la catergoria enterohemorrágica, caracterizando además un aislamiento reportado como serotipo 0157:H7 procedente de la ciudad de Tacna (cepa Tacna 410), mediante la reacción en cadena de la polimerasa (PCR) y secuenciamiento. Los resultados confirmaron la presencia del gen de la toxina shiga sólo en la cepa Tacna 410, obteniéndose una identidad del 100 por ciento entre la secuencia nucleótida del gen de la copa Tacna 410 y secuencias reportadas de la toxna shiga de tipo II en el Genebank. Asimismo, se detectó en la cepa Tacna 410 propiedades hemolíticas y el gen eae asociado al fenómeno de attaching and effacing, características de una típica cepa de ECEH.

We tried to detect the Shiga gene in local Escherichia Coli strains serologically related the enterohemorragic category. At the same time, using polymerase chain reaction (PCR) and sequencing, we characterized a strain confirmed as E. Coli 0157:H7 serotype, which was isolated in Tacna (a city in southern Peru) (Tacna 410 strain). Our results confirmed the presence of the Shiga toxin gene only in E. coli strain Tacna 410, and we found 100 percentage identify between the sequence from the amplified gene and reference sequence for type II Shiga toxin in the gene bank. We also detected in the Tacna 410 strain hemolytic properties and the eae gene, which is associated to attaching and effacing lesions, typical features of EHEC, strains.

Assuntos

RESUMO

Objetivos. Evaluar la carga de morbilidad de la diarrea por rotavirus en Perú, la necesidad de una vacuna y el ahorro que esta podría proporcionar en este país. Métodos. Para evaluar la carga de morbilidad de la diarrea por rotavirus en Perú, se revisaron los estudios publicados y no publicados sobre los rotavirus como causa de diarrea en niños. Las tasas de detección de rotavirus en estos estudios se combinaron con las tasas de incidencia de diarrea procedentes de varias encuestas nacionales, con el fin de estimar tanto la carga de morbilidad de la diarrea por rotavirus como sus costos médicos. Resultados. Los rotavirus son una importante causa de morbilidad y mortalidad en los niños peruanos. Se estima que, en sus primeros 5 años de vida, 1 de cada 1,6 niños sufre un episodio de diarrea por rotavirus, que 1 de cada 9,4 busca atención médica, que 1 de cada 19,7 necesita ser hospitalizado y que 1 de cada 375 muere por esta causa. Cada año, esto representa aproximadamente 384 000 casos, 64 000 consultas, 30 000 hospitalizaciones y 1 600 muertes. El costo anual únicamente de la atención médica de estos niños es de aproximadamente 2,6 millones de dólares estadounidenses, sin tener en cuenta los costos indirectos o sociales de la enfermedad y las muertes. Conclusiones. La vacunación contra los rotavirus permite albergar la esperanza de reducir la morbilidad y mortalidad de la diarrea en Perú, pero el régimen de vacunación debería ser relativamente barato (unos pocos dólares por niño). En el futuro, los análisis de costo-efectividad deberían investigar los costos totales (tanto los médicos como los indirectos o sociales) de la diarrea por rotavirus, y las vacunas que se aprueben deberían ser probadas en lo que se refiere tanto a su capacidad para evitar las muertes como a su eficacia con menos de tres dosis. Estos tres factores podrían incrementar el ahorro proporcionado por la vacuna contra los rotavirus

Objective. To assess the disease burden of rotavirus diarrhea in Peru as well the need for and the potential cost savings with a rotavirus vaccine in that country. Methods. To assess the burden of rotavirus diarrhea in Peru, we reviewed published and unpublished reports where rotavirus was sought as the etiologic agent of diarrhea in children. Rotavirus detection rates obtained from these studies were combined with diarrhea incidence rates from a number of national surveys in order to estimate both the burden of rotavirus diarrhea in the country and its associated medical costs. Results. Rotavirus is a significant cause of morbidity and mortality in Peruvian children. In their first 5 years of life, an estimated 1 in 1.6 children will experience an episode of rotavirus diarrhea, 1 in 9.4 will seek medical care, 1 in 19.7 will require hospitalization, and 1 in 375 will die of the disease. Per year, this represents approximately 384 000 cases, 64 000 clinic visits, 30 000 hospitalizations, and 1 600 deaths. The annual cost of medical care alone for these children is approximately US$ 2.6 million­and that does not take into account the indirect or societal costs of the illness and the deaths. Conclusions. Rotavirus immunization provides the prospect of decreasing the morbidity and mortality from diarrhea in Peru, but a vaccine regimen would have to be relatively inexpensive, a few dollars or less per child. Future cost-effectiveness analyses should explore the total costs (medical as well as indirect or societal) associated with rotavirus diarrhea. Newly licensed vaccines should be tested according to both their ability to avert deaths and their efficacy with fewer than three doses. All three of these factors could increase the cost savings associated with a rotavirus vaccine

Assuntos

Assuntos

RESUMO

La hipótesis de que los virus pudieran ser causa de diarrea aguda se postuló desde hace mucho, principalmente por la baja frecuencia del aislamiento de bacterias en las heces de pacientes con esta enfermedad. Claro que entonces se conocían sólo unas cuantas bacterias Salmonella, Shigella y Escherichia coli enteropatógena a lo más pero, aun ahora, con más de 25 microorganismos reconocidos como causa de diarrea, no más de 30-40 por ciento de los casos debidos a alguna bacteria o parásito. En la década de los 40 y 50 estudios experimentales comprobaron el carácter trasmisibles de partículas filtradas, libres de bacteria, obtenidas de casos de gastroenteritis infantil y administradas oralmente a animales de laboratorio y voluntarios humanos. El término gastroenteritis epidémica no bacteriana se acuño para referirse a las diarreas de origen presumiblemente viral

Assuntos

RESUMO

Aunque los temas de este seminario incluían tanto la enfermedad diarreica como las infecciones respiratorias agudas, las propuestas preparadas por los participantes se refieren sólo a la educación médica en tema de EDA. Este informe ha sido preparado para difundir entre las partes interesadas, las importantes conclusiones y recomendaciones a las que se llegaron al final del evento, asi como las propuestas preparadas por los participantes para ser aplicadas en sus respectivas instituciones en los futuros cursos de pediatría

Assuntos

RESUMO

Los paquetes conteniendo la mezcla de glucosa-electrolitos recomendada por la Organización Mundial de la Salud (OMS) para la rehidratación oral pueden hacerse inservibles cuando se almacenan bajo condiciones de humedad debido a que la glucosa sufre un proceso de polimerización, en una reacción favorecida por el bicarbonato de sodio, que causa un oscurecimiento de la mezcla y disminución de su solubilidad. La sustitución del bicarbonato por el citrato de sodio, sin embargo, mejora marcadamente la estabilidad de la mezcla. En un ensayo clínico randomizado, doble ciego, hemos comparado la eficacia de una solución de Rehidratación Oral (SRO)- conteniendo citrato con la SRO - conteniendo bicarbonato en el tratamiento de niños con deshidratación diarreica admitidos al Departamento de Pediatría del Hospital de la Universidad Cayetano Heredia. Noventaisiete niños, de tres a 24 meses de edad fueron estudiados; 49 fueron tratados con la SRO - conteniendo bicarbonato y 48, con la SRO - conteniendo citrato . Los dos grupos fueron similares en todos los parámetros medidos al empezar el tratamiento. El tratamiento fue igualmente eficaz en ambos grupos determinado por la respuesta clínica y el flujo fecal. La rehidratación oral fue exitosa (esto es, no se requirió fluidos endovenosos durante el tratamiento) en 85 por ciento de los pacientes estudiados; la tasa de éxito fue similar en ambos grupos. La concentración sérica de CO2 total incrementó de un modo similar en ambos grupos alzando valores casi normales a las 48 horas después de la admisión. Concluímos que el citrato de sodio puede sustituir al bicarbonato en la formulación de la SRO recomendado por la OMS para el tratamiento de rehidratación oral de niños con deshidratación diarréica.

Assuntos